Alembic Pharmaceuticals growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+10.1%+7.1%+10.2%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+10.9%+8.0%+31.8%
+9.6%+10.4%+52.6%
+15.3%−5.5%+80.1%
+15.7%−5.3%+80.1%
+12.7%+20.6%+4.2%
+9.2%+7.7%+10.2%
+789.8%−89.0%+10.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

APLLTD₹794.85

Alembic Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersAJANTPHARMIPCALABTORNTPHARMALIVUSAKUMSAGARWALEYEADVENZYMESAARTIPHARMMcap ₹15,623 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+10.2+7.1+10.1—
EBITDA Growth—+31.8+8.0+10.9—
EBIT Growth—+52.6+10.4+9.6—
Net Income Growth—+80.1-5.5+15.3—
EPS Growth—+80.1-5.3+15.7—
Total Assets Growth—+4.2+20.6+12.7—
Total Equity Growth—+10.2+7.7+9.2—
Cash from Operations Growth—+10.9-89.0+789.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.